Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2017

Open Access 01-04-2017 | Original Article

Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway

Authors: Trine Levin, Lovise Mæhle

Published in: Familial Cancer | Issue 2/2017

Login to get access

Abstract

Germline mutations in the CDKN2A gene are associated with an increased risk of malignant melanoma and pancreatic cancer. In order to find out if the behavior pattern in families with a CDKN2A mutation is similar to what we previously have described in families with a BRCA1 mutation, we have studied the uptake of genetic services in probands and their relatives. We describe whether they attend genetic counseling when invited, whether they want a mutation test after being counseled and whether they adhere to recommendations for surveillance. 66 % (95/144) of first-degree relatives to mutation carriers contacted us within the study period. 98 % (126/128) of all relatives who came for genetic counseling decided on genetic testing for their family’s mutation, and 93 % (66/71) of all mutation carriers wanted referral to yearly skin examinations. Female relatives had a significantly higher uptake of genetic services compared to males, similar to the findings in families with a BRCA1 mutation. Uptake of genetic services in general in families with a CDKN2A mutation is high. Females seem to have a higher interest in genetic testing than males, regardless of gene mutated.
Literature
1.
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J et al (1994) Analysis of the p16 gene (CDKN2A) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8(1):23–26CrossRefPubMed
2.
Zuo L, Weger J, Yang O, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97–99CrossRefPubMed
3.
Biesecker BB, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman C, Struewing JP (2000) Psychosocial factors predicting BRCA1/BRCA2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 93(4):257–263CrossRefPubMed
4.
Julian-Reynier C, Sobol H, Sévilla C, Noguès C, Bourret P, Network FCG (2000) Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psycho Oncol 9(6):504–510CrossRef
5.
Reichelt JG, Dahl AA, Heimdal K, Møller P (1999) Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations. Dis Markers 15(1–3):139–143CrossRefPubMedPubMedCentral
6.
Bodd TL, Reichelt J, Heimdal K, Moller P (2003) Uptake of BRCA1 genetic testing in adult sisters and daughters of known mutation carriers in Norway. J Genet Couns 5:405–417CrossRef
7.
Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA (1995) Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 4(2):169–173PubMed
8.
Foster C, Evans DG, Eeles R, Eccles D, Ashley S, Brooks L, Davidson R, Mackay J, Morrison PJ, Watson M (2002) Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. Br J Cancer 86(8):1209–1216CrossRefPubMedPubMedCentral
9.
Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA, Melanoma Genetics Consortium (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94(12):894–903CrossRefPubMed
10.
11.
Cancer Registry of Norway (2015) Cancer in Norway 2014—cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, Oslo
12.
Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA (2008) Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas. Genes Chromosomes Cancer 47(2):175–184CrossRefPubMed
13.
Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16ink4 mutations. N Engl J Med 333:970–974CrossRefPubMed
14.
Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET, Bergman W (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87(6):809–811CrossRefPubMed
15.
Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, Melanoma Genetics Consortium (GenoMEL) (2006) High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66(20):9818–9828CrossRefPubMed
16.
Potrony M, Puig-Butille JA, Aguilera P, Bandenas C, Carrera C, Malvehy J, Puig S (2014) Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol 71(5):888–895CrossRefPubMedPubMedCentral
17.
18.
Helgadottir H, Höiom V, Jönsson G, Tuominen R, Ingvar C, Borg Å, Hansson J (2014) High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 51(8):545–552CrossRefPubMedPubMedCentral
19.
20.
Levin T, Reichelt J, Heimdal K, Møller P (2001) Informasjonsflyt i familier med arvelig bryst-og eggstokkreft. [Information to families with hereditary breast and ovarian cancer]. Tidsskr Nor Laegeforen 121(28):3292–3294PubMed
21.
Stoffel EM, Mercado RC, Kohlmann W, Ford B, Grover S, Conrad P, Blanco A, Shannon KM, Powell M, Chung DC, Terdiman J, Gruber SB, Syngal S (2010) Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol 105(8):1851–1860CrossRefPubMedPubMedCentral
22.
Lammens CR, Bleiker EM, Aaronson NK, Wagner A, Sijmons RH, Ausems MG, Vriends AH, Ruijs MW, van Os TA, Spruijt L, Gómez García EB, Cats A, Nagtegaal T, Verhoef S (2010) Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer 9(4):647–654CrossRefPubMedPubMedCentral
23.
Kasparian NA, McLoone JK, Meiser B, Butow PN, Simpson JM, Mann GJ (2010) Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma. Br J Cancer 103:1502–1509CrossRefPubMedPubMedCentral
24.
Aspinwall LG, Leaf SL, Dola ER, Kohlmann W, Leachman SA (2008) CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev 6:1510–1519. doi:10.​1158/​1055-9965.​EPI-08-0010 CrossRef
25.
Gaff CL, Collins V, Symes T, Halliday J (2005) Facilitating family communication about predictive genetic testing probands’ perceptions. J Genet Couns 14(2):133–140CrossRefPubMed
26.
27.
Richards M (1996) Families, kinship and genetics. In: Marteau T, Richards M (eds) The troubled helix: social and psychological implications of the new human genetics. Cambridge University Press, New York, pp 249–273CrossRef
28.
Metadata
Title
Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway
Authors
Trine Levin
Lovise Mæhle
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9939-8

Other articles of this Issue 2/2017

Familial Cancer 2/2017 Go to the issue

Letter to the Editor

Colonoscopy in Lynch syndrome: the need for a new quality score

Short Communication

Analysis of a RECQL splicing mutation, c.1667_1667+3delAGTA, in breast cancer patients and controls from Central Europe

Original Article

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer

Original Article

Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the Netherlands

Original Article

All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients

Original Article

Attenuated polyposis of the large bowel: a morphologic and molecular approach
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits